SEC Filing | Nuwellis, Inc.

View:

Filed Pursuant to Rule 433 of the Securities Act of 1933
Registration Statement No. 333-235385
Issuer Free Writing Prospectus dated January 7, 2020

Safe Harbor Statement For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the future that are intended to be covered by the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, all forward-looking statements are management’s present expectations and are not guarantees of future events and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “plan,” “predict,” “potential,” “project,” “promising,” “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “milestone,” and similar expressions and variations thereof. Various factors could cause actual results to differ materially from these statements including our ability to execute on our commercial strategy and to grow our Aquadex FlexFlow® business, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our expectations regarding anticipated synergies with and benefits of the Aquadex FlexFlow business, our business strategy, market size, potential growth opportunities and the other risks set forth under the caption “Risk Factors” and elsewhere in our periodic and other reports filed with the U.S. Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. We are providing this information as of the date of this presentation we undertake no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Although the Company believes that the forward-looking statements are reasonable and based on information currently available, it can give no assurances that the Company’s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. These data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.Aquadex FlexFlow® is a registered trademark of CHF Solutions, Inc. Aquadex SmartFlow™ is a trademark of CHF Solutions, Inc.

Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all ofthe other information contained in our SEC filings. If any of the following risks actually occurs, our business, financial condition, results ofoperations and future prospects would likely be materially and adversely affected. This could cause the market price of our securities to decline and could cause you to lose all or part of your investment. Risks include but are not limited to:We are currently seeking 510(k) FDA approval of the Aquadex FlexFlow System for use in pediatrics, however, there is no guarantee that we will receive approval from the FDA.We have a limited history of operations and limited experience in sales and marketing, and we might be unsuccessful in increasing our sales and cannot assure you that we will ever generate substantial revenue or be profitable.Our near-term prospects are highly dependent on revenues from a single product, the Aquadex FlexFlow system. We face significant challenges in expanding market acceptance of the Aquadex FlexFlow system, which could adversely affect our potential revenues.We do not have commercial manufacturing experience and could experience difficulties in producing commercial volumes of the Aquadex FlexFlow system and related components or may need to depend on third parties for manufacturing. For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 3 We believe that we will need to raise additional capital to fund our operations beyond 2020. If additional capital is not available, we will have to delay, reduce or cease operations.We depend upon third-party suppliers, including single source suppliers, making us vulnerable to supply problems and price fluctuations.If we cannot develop adequate distribution, customer service and technical support networks, then we may not be able to market and distribute the Aquadex FlexFlow system effectively and our sales will suffer.The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, we may not be able to sustain or grow our business.The company may face significant risks associated with international operations, which could have a material adverse effect on business, financial conditions and results of operations.Nasdaq may delist our common stock from its exchange which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.The company has a large number of authorized but unissued shares of stock, which could negatively impact a potential investor if they purchased the common stock.The company is a “smaller reporting company” under federal securities laws and the company cannot be certain whether the reduced reporting requirements applicable to such companies will make the common stock less attractive to investors. Risk Factors

Statement about Free Writing Prospectus For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 4 This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our company. Except as otherwise indicated, this presentation speaks only as of the date hereof.This presentation does not constitute an offer to sell, nor a solicitation of an offer to buy, any securities by any person in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation.Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of our securities or passed upon the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense.This presentation includes industry and market data that we obtained from industry publications and journals, third-party studies and surveys, internal company studies and surveys, and other publicly available information. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this presentation, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions that were used in preparing the forecasts from the sources relied upon or cited herein.We have filed a Registration Statement on Form S-1 with the SEC, including a preliminary prospectus dated January 3, 2020 (the “Preliminary Prospectus”), with respect to the offering of our securities to which this communication relates. Before you invest, you should read the Preliminary Prospectus (including the risk factors described therein) and, when available, the final prospectus relating to the offering, and the other documents filed with the SEC and incorporated by reference into the Preliminary Prospectus, for more complete information about us and the offering. You may obtain these documents, including the Preliminary Prospectus, for free by visiting EDGAR on the SEC website at http://sec.gov.Alternatively, we or any underwriter participating in the offering will arrange to send you the prospectus if you request it by contacting Ladenburg Thalmann & Co. Inc., Attn: Prospectus Department, 277 Park Avenue, 26th Floor, New York, NY 10172, by calling (212) 409-2000 or by email at prospectus@ladenburg.com.

Our Vision For Investor Purposes Only: Not For Product Promotion 5©2020 CHF Solutions, Inc. For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. CHF Solutions is dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation.

6 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. Addressable Target Segments 1. Subject to FDA 510(k) clearance Critical CareCV Surgery (VAD, CABG, HV)*Liver (Transplant, Disease)SepsisAdult ECMO*strategic entry poin t Heart FailureInpatientOutpatient urgery nts Pediatric1Renal ReplacementHeart DiseaseCardiac STransplaECMO Commercialization We are transitioning from a primary focus on the chronic needs in heart failure, to the acute needs in cardiac surgery and we anticipate soon to the life-saving therapy in pediatric care Expect FDA 510(k) Clearance Early 2020 Multiple On-Going Studies

Upcoming Key Milestones Upcoming Key Milestones For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 7 Expected Timing Q1 2020 FDA 510(k) clearance of:Expanded use in pediatric population (≥ 20kg)Next generation Aquadex SmartFlow™ consoleReceive CE mark for Aquadex SmartFlowU.S. pediatric market introduction of Aquadex SmartFlowInitiate Tampa VA clinical study on outpatient use of Aquadex SmartFlowExpanded clinical study results of aquapheresis in tandem with extracorporeal Q1 2020Q2 2020Q2 2020Q2 2020 Q2 2020 membrane oxygenation (ECMO) in pediatric patientsSubmit Category I CPT code application for aquapheresis using Aquadex SmartFlowResults of Mt Sinai 200 patient retrospective study in post cardiovascular surgery to be published at American College of Cardiology (ACC) meeting (submission October 2020) Q3 2020 Abington-Jefferson retrospective single-center heart failure study to be published at Heart Failure Society of America (HFSA) Final publication of therapy into advanced liver disease (pre & post transplant) at Mt. Sinai Hospital. Q3 2020Q4 2020

Simple Easy set-up and monitoring allowing for a 4:1 nurse to patient ratio Flexible Deliver safe and precise therapy with the ability to adjust the fluid removal rate and volume to meet each patient’s clinical need Smart Filter Alert prompts action to extend life and reduce therapy timeHct informs therapy triage and termination decisionsSv02 to help determine the amount of oxygen delivered to the body and guide therapy decisionsTrack fluid removed more easily than today’s manual process Next Generation Aquadex New ease of use and diagnostic features that provide therapeutic insights are expected to result in greater account penetration (more consoles per account) and utilization (more circuits per console) Expect FDA 510(k) Clearance Early 2020 Expect CE Mark Q1 2020 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 8

Competitive Landscape Ultrafiltration (Dedicated) Pediatrics Ultrafiltration Critical Care – Continuous Renal Replacement Therapy (“CRRT”) U.S. / Int’l Approval Pending 510(k) (est. early 2020) & Int’l Approval Potential for more effective treatment with Aquadex - - U.S. / Int’l Approval - - U.S. / Int’l Approval - - Int’l Approval No US Approval Int’l Approval No US Approval Int’l Approval No US Approval Int’l Approval No US Approval - - Int’l Approval No US Approval The Aquadex SmartFlow offers a new and differentiated treatment in critical underserved markets: For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 9

Pediatric Opportunity “For our babies born with diseased or absent kidneys, Aquadex has given them a chance at life because in the past, there were no options to treat these patients.”Kara Short, MSN, CRNP, NICU nurse practitioner at Alabama Children’s Hospital For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 10

Pediatrics: Providing a Solution in an Underserved Market https://www.ncbi.nlm.nih.gov/pubmed/23833312https://www.cdc.gov/ncbddd/heartdefects/data.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/23246046.https://www.organdonor.gov/about/donors/child-infant.html.http://www.heartviews.org/article.asp?issn=1995- 705X;year=2016;volume=17;issue=3;spage=92;epage=99;aulast=Jayaprasad Aquadex FlexFlow/ultrafiltration is currently being prescribed (off-label use) by physicians to treat various pediatric conditionsAcuteKidney replacement therapy (11,000 patients/yr)1Cardiac surgery (10,000 procedures/yr)2Extracorporeal membrane oxygenation (ECMO) therapy (6,000 procedures/yr)3Solid organ transplantation (2,000 procedures/yr)4ChronicHeart Disease (12,000 patients/yr)5 Expect FDA 510(k) label expansion in pediatrics early 2020 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 11

Attributes Grp 1: <10 kg Grp 2: 10-20kg Grp 3: >20 kg # of patients N=72 N=13 N=34 Median age 19 days 26 months 190 months Median weight at therapy onset 4.1 kg 15.1 kg 60.1 kg Primary disease 43% kidney 54% kidney 38% kidney 29% cardiac 31% other 38% cardiac Predominant indication 46% Volume overload 54% Volume overload 91% Volume overload Common modality 67% CVVH 62% CVVH 92% SCUF Median blood flow rate, ml/min 40 40 40 Median # days on UF 9 7 1 Median # of circuits 4 3 2 Cardioresp. support at initiation (orw/ complications at initiation) 3% 7% 0% Survival at end of treatment 43 (60%) 13 (100%) 33 (97%) Survival at hosp discharge 23 (32%) 11 (85%) 23 (68%) Survival at 1-yr 12 (52%) 8 (73%) 14 (67%) Transient hypotension Transient hypotension (3), Transient hypotension (4), Most prevalent complications (30), filter clot (37) filter clot (9) filter clot (6) Aquadex is Providing Pediatric Patients at High Risk of Mortality an Opportunity at Life Group 1 patients would traditionally not receive any kind of therapy Clinical Data Overview: Patients who received therapy with Aquadex FlexFlow from January 2012 – March 2018 (n=119 admissions, 884 circuits); Three centers: Children’s of Alabama, Cincinnati Children’s Hospital and Seattle Children’s Hospital (Menon S. et al. CJASN. August 28, 2019) Patient’s Weight Survival Rate with Aquadex < 10kg 60% 10kg – 20kg 100% > 20kg 97% For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 12 Subject to FDA 510(k) clearance for pediatric use

Children’s of Alabama – Pioneer of Aquadex Use in Pediatrics Pediatric use of the Aquadex FlexFlow was first introduced at Children’s of Alabama in 2016 by Dr. David Askenazi1Today, 97% of therapy initiations occur without hemodynamic changes, meaning that the hospital gets pediatric patients on the machine safely2 Sample Pediatric Patient Case Study3 Age 2.5 years Average Weight for Age 30 lbs. Actual Weight with Fluid Overload 50 lbs. Prior to Aquadex Treatment Nephrotic syndromeNo response to diuretics or other therapiesUnable to walkPotential risk to heart and lung function Aquadex Treatment Daily treatment for 2 weeks Result Removal of 20 lbs. of fluid Children critically ill with fluid overload from heart failure, liver failure and sepsis have also benefitted from the use of Aquadex FlexFlow1 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 13 Subject to FDA 510(k) clearance for pediatric use Aquadex FlexFlow® modified for pediatric use by staff at Children’s of Alabama without promotion or training by CHF SolutionsBirmingham Medical News “Adapting Technology Saves Tiny Patients”; December 17, 2019Sample patient case study. Individual clinical results may vary

14 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. Pediatric Opportunity, Pipeline & Regulatory Status The Aquadex FlexFlow is being used in 24 metro areas in the U.S. for pediatric use without sales and marketing by CHF Solutions (pending 510(k) clearance for pediatric use) City / State Colorado Springs, CO Corpus Christi, TX Dallas, TX Gainesville, FLGrand Rapids, MIIndianapolis, IN Kansas City, MO Lexington, KY Minneapolis, MN Washington D.C. Phase 1Initiate Contact1 Phase 2 Approval2 City / State Chicago, IL Columbus, OH Houston, TX San Diego, CA Pittsburg, PA Phase 3Implementation3 City / State Dayton, OH Hollywood, FL Palo Alto, CA Wilmington, DE Philadelphia, PA Phase 4Adoption4 City / State # of Units Birmingham, AL Cincinnati, OH Miami, FL 553 Seattle, WA 3 Total Units 16 Center contacted CHFS and communication has been establishedClinical training scheduled and necessary product purchasedClinical staff trained and therapy has startedTherapy being used on a regular basis 33% of revenue in Q4 2019 At Phase 2 the Aquadex FlexFlow is purchased With no promotion by CHF Solutions

15 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. Joe DiMaggio Children’s Hospital Uses Aquadex FlexFlow In Tandem With ECMO In Pediatric Patients Extracorporeal Membrane Oxygenation (ECMO) is an advanced form of life support that does the work of the heart and lungs when those organs are failingChildren with cardiopulmonary failure requiring ECMO are at risk for fluid overload; it has been shown that survival in the ICU is inversely proportional to fluid overload1 Sample ECMO + Aquadex Pediatric Patient Case Study1,2 Age 4 years Indication for ECMO Septic Shock due to Streptococcus Pyogenes Indication for AQ Fluid Removal because of AKI stage 3 Outcome Initiated AQ on ECMO day 3Remove ECMO and AQ on ECMO day 4Transferred out of PICU on hospital day 13 Aquadex Treatment 17 hours Result Patient discharged home on hospital day 18 The use of Aquadex FlexFlow provides a simplified and safe form of fluid removal with minimal impact on ECMO therapy and renal function1 Aquapheresis (AQ) in Tandem with Extracorporeal Membrane Oxygenation (ECMO) in Pediatric Patients; J Extra Corpor Technol. 2019;51:163–8Sample patient case study. Individual clinical results may vary Subject to FDA 510(k) clearance for pediatric use

Many large-volume hospitals use Aquadex FlexFlow as a treatment for fluid overload in the ICU settingThe clinical reason for fluid overload in critically ill patients is related to the requirement for fluid resuscitation (infusion of fluids to maintain hemodynamics)In a retrospective study of Aquadex FlexFlow utilization at Lenox Hill Hospital in NYC, 23 patients were treated safely in situations, other than heart failure, without effecting renal function1 Critical Care: Ultrafiltration Critical to Success in Fluid Overloaded, Critically Ill Patients Cardiothoracic Intensive Care Unit (ICU)Critical Care UnitMedical ICUSurgical ICU Hospital Location Where Aquadex FlexFlow is Used in Critically Ill Patients1 Indications for Prescribing Aquadex FlexFlow in Critically Ill Patients1 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 17 Cardiogenic shock, including post CTSAnasarca (general tissue fluid accumulation)Acute Tubular Necrosis (ATN) with volume overloadEnd-stage renal disease between hemodialysisPost-operative volume overload 1. Aquapheresis: An Institutional Experience at Lenox Hill Hospital (Abstract presented a the 2019 ANS)

Critical Care Growth Opportunities Cardiac Surgery(Valves, CABG)Liver Transplants VAD Adult ECMO Sepsis Liver Disease 520,000 patients/year1 8,000 patients/year2 - Emerging use in indication- Independent clinical data being generated Evaluating market Sepsis 1.7m patients/year4 Liver Disease 650,000 patients/year5 Adult ECMO 120,000 patients/year 6 STATUS STATUS Est. Market Size Est. Market Size Near-Term Opportunities Long-Term Opportunities Current commercialization effortsOngoing single center prospective study of therapy in advanced liver disease- Emerging use in indication- Actively targeting U.S. and European centers 4,000 patients/year3 Additional Potential Markets General traumaBurnsOther solid organ transplants https://www.grandviewresearch.com/industry- analysis/coronary-artery-bypass-graft-cabg-markethttps://www.healthline.com/health/liver-transplant- survivalGrand View Research. Market Research Report. 2015; 978- 1-68038-603-5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557150/https://www.ncbi.nlm.nih.gov/pubmed/25291348https://www.ncbi.nlm.nih.gov/pubmed/30247176 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 18

Acute Need in Cardiac Surgery: Fluid Overload is Associated with Greater Mortality Retrospective analysis on 1,358 patients who underwent cardiac surgery Greater amount of IV fluid during cardiac surgery associated with three-fold increase in mortality at 90 days Fluid Overload is Associated with 300% Increase in 90 Day Mortality Rates Post CV Surgery Source: Pradeep, A. et al. HSR Proc IC and Car An. 2010 Mar; 2(4): 287-296 Survival rates with Excess Fluid For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 19 Survival rates with No Excess Fluid

Aquadex FlexFlow Provides Significant Clinical and Economic Benefits in CV Surgery Modified ultrafiltration reduces duration of assisted ventilation post cardiac surgery1,2,3Ultrafiltration associated with decreases in certain post-operative complications4,5,6,7Aquadex FlexFlow not considered renalreplacement therapy from a quality reporting standpointNo Nephrology consultation required to prescribe Aquadex FlexFlowFeatured sponsorship of CV usage discussion atSociety of Thoracic Surgeons by Daniel Beckles, M.D., Ph.D. 1.Luciani GB, et al. Circulation. 2001 Sep 18;104(12 Suppl 1): I253-I259. 2. Kiziltepe, U, et al. Ann Thorac Surg. 2001 Feb;71(2): 684-93. 3. Grunenfelder et al. Eur J of Cardio-Thoracic surgery.2000; 17:77-83. 4. Sahoo TK, et al. Indian J Thorac Cardiovas Surg. 2007 Jun;23(2):116-124. 5. Boodhwani M et al. Eur J Cardiothorac Surg. 6. Torina et al. J of Thorac Cardiovasc Surg. 2012;144:663-70. 7. Papadppoulos et al. Perfusion. 2013;28:306-14. For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 20

Over 1 million heart failure (“HF”) hospitalizations annually in the US and 90% of these are due to fluid overload168% show sub-optimal response, 40% exhibiting diuretic resistance (“failure”)3. Nearly 50% of patients are discharged with residual excess fluid1Worsening heart failure with increased mortality after discharge1Several publications support the use of Aquadex FlexFlow to lower re- hospitalization rates in CHF patients1Per patient savings of $3,975 over 90 days when Aquadex FlexFlow is used compared to diuretics2 Heart Failure (“HF”) – Opportunity in the 30 Days Readmission Patient Population 1. Costanzo MR, et al., J Am Coll Cardiol., 2017; 69: 2428-45 2. Costanzo MR et al., Poster presented at ISPOR 23rd Annual International Meeting, May 19-23, Baltimore, MD, USA. 3. Testani, Circ Heart Failure, 2016;9:e002370 Q2: Attended CPT Editorial Panel Meeting Q3: Gained support of specialty societies for application Q4: ACC Coding Committee recommended aquapheresis using Aquadex for Cat. 1 CPT code Q2: Submit Cat. I CPT code application Q4: Notification of new Cat. 1 CPT code(if approved) Q1: Effective date of new Cat.1 CPT code (if approved) Expect to submit Category I CPT code application for aquapheresis using Aquadex SmartFlow in Q2 20202019 2020 2021 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 22 2022

Tampa VA Clinical Study on Outpatient Use of AquadexGoal: Manage HF patients proactively to avoid 30-day readmissions$6.5M blanket purchase agreement received for outpatient trialAquadex FlexFlow vs. IV diuretics in outpatient settingProspective, randomized 80 patient studyQ2 2020 initiation - IRB Approved. Awaiting first patient.Primary outcomes: weight change and rehospitalizationsSecondary endpoints: fluid removal, renal function, cost effectiveness, QOL, etc. Outpatient Opportunity Update Active Aquadex FlexFlow Outpatient ProgramsMedStar Good Samaritan Hospital (Baltimore, MD)Advocate Good Samaritan Hospital (IL)Aquadex FlexFlow Outpatient Program PipelineOklahoma Heart Institute (OK)Christ Hospital (Cincinnati, OH)Ohio State University (Columbus, OH)Expect to submit Category I CPT code application in Q2 2020 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 23

US direct sales team of 13 sales territories and 14 clinical education specialistsDistribution partners in UK, Italy, Germany, Spain, Greece, Singapore, Hong Kong, Thailand, India & Brazil Expanding Commercial Distribution In Q3/Q4 2019, we refocused our sales force towards the cardiac surgery and pediatrics markets For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 24

Financial Metrics US Pediatric Revenue as % of US Product Revenue $ in 000s Q3 2019: clinical pediatric publicationQ3-Q4 2019: commenced salesforce refocus to cardiac surgery and pediatrics 2019 Quarterly Revenue 2019 Quarterly Gross Margin Note: Q4 2019 numbers are preliminary Comments For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 26

Comparable Pediatric and Critical Care Companies 89% discount for a company with U.S. product sales, no debt, an FDA approved device and an additional indication pending clearance Pediatric/ critical care nitric oxide delivery deviceNot FDA approved Market Cap + Debt ($0.3M) = $91M1 LTM Product Sales = $02 Critical care blood purification deviceNot FDA approved Market Cap + Debt ($16.2M) = $139M1 LTM Product Sales = $21.6M (int’l)2 Fluid overload treatment deviceFDA approvedPediatrics & Critical CareFDA clearance pending in pediatrics Market Cap + Debt ($0) = $4.0M LTM Product Sales = $5.5M LTM Product Sales Multiple = 0.7x Comparison to peers have limitations and material characteristics that may differ from the subject comparison. For informational purposes only For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 27 Beyond Air, Inc. (NASDAQ:XAIR) Cytosorbents Corp. (NASDAQ:CTSO) LTM Product Sales Multiple = 6.5xAs of January 7, 2020As of September 30, 2019

Capitalization as of December 31, 2019 Common Stock or Equivalents Common Shares Outstanding (Nasdaq CHFS) 4,674,068 Series F Convertible Preferred1 538,210 Options (weighted average exercise price $21.56) 405,730 Warrants2 (weighted average exercise price $7.06) 6,948,466 Fully Diluted Shares 12,566,474 For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 28 Capitalization Cash as of December 31, 2019: $1.3MNo debt 535 shares convertible at $0.9942 per share, anti-dilution rightsConsists of: a) 4.7 million Series 1 and Series 2 warrants exercisable at $5.25, half expire within 30 days of announcement of a pediatric label modification by the FDA, half expire Mar 2024, b) 1,219,076 warrants exercisable at $0.9942, expiring Nov 2024,c) 575,830 warrants exercisable at $1.41 expiring Apr 2025, d) 277,161 warrants exercisable at $29.7, expiring in Nov 2024; e) 9,494 warrants exercisable at $63.0, expiring Nov 2024; and f) 135,477 warrants exercisable at a weighted average exercise price of $98.7, expiring Feb 2022-Feb 2025. No anti-dilution provision on any warrants.

Medical device company with near- and long- term growth opportunities:Pediatrics: providing a solution to an underserved market; seeking 510(k) clearanceCardiac Surgery & Critical Care: Leveraging acute need to reduce mortality and drive adoption with clinical/economic benefitsHeart Failure: Largest market opportunity. Increasing focus in outpatient hospital clinics and leveraging Tampa VA outpatient clinical studySales force focus on new underserved market opportunitiesAnticipated key milestones in 2020 including, but not limited to:Pediatric 510(k) clearance: early 2020Tampa VA first patient enrollment in outpatient study – Q2 2020Clinical publications for use in CV Surgery, HF and advanced Liver disease in Q3/Q4 2020Therapy initiation in several hospital systems for Pediatrics, CV Surgery, and advanced Liver disease For Investor Purposes Only: Not For Product Promotion©2020 CHF Solutions, Inc. 29 CHF Solutions Investment Considerations